Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Capital Expenditures (2018 - 2025)

10x Genomics' Capital Expenditures history spans 8 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 34.57% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $5.9 million, down 52.11%, while the annual FY2025 figure was $5.9 million, 52.11% down from the prior year.
  • Capital Expenditures for Q4 2025 was $1.8 million at 10x Genomics, up from $687000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $88.6 million in Q4 2021 and bottomed at -$40.7 million in Q3 2021.
  • The 5-year median for Capital Expenditures is $5.6 million (2024), against an average of $15.0 million.
  • The largest YoY upside for Capital Expenditures was 4180.67% in 2021 against a maximum downside of 447.2% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $88.6 million in 2021, then plummeted by 55.14% to $39.7 million in 2022, then grew by 15.02% to $45.7 million in 2023, then plummeted by 94.06% to $2.7 million in 2024, then crashed by 34.57% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Capital Expenditures are $1.8 million (Q4 2025), $687000.0 (Q3 2025), and $3.1 million (Q2 2025).